strong>Soricimed Biopharma Inc., of Toronto, presented a poster at PEGS, a protein engineering summit in Boston, showing that SOR-C13, a cancer peptide therapeutic targeting the TRPV6 oncochannel, showed efficacy in breast and ovarian cancer xenografts in a murine model.